Results from the phase III 006 Study of Cytalux (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer reports that use of Cytalux during ovarian cancer surgery demonstrated identification of additional lesions that were not identified with conventional means and not otherwise planned for resection.
Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.
